Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 72Lymphoma 63Lymphoma, Follicular 59Lymphoma, Mantle-Cell 58Lymphoma, Large B-Cell, Diffuse 40Hodgkin Disease 32Lymphoma, B-Cell, Marginal Zone 28Recurrence 25Lymphoma, B-Cell 19Leukemia 17Waldenstrom Macroglobulinemia 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasms 11Lymphoma, T-Cell 7Burkitt Lymphoma 7Lymphoma, T-Cell, Peripheral 6Leukemia, Myeloid, Acute 6Leukemia, B-Cell 6Sezary Syndrome 5Mycosis Fungoides 5Multiple Myeloma 5Immune System Diseases 5Myelodysplastic Syndromes 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Lymphatic Diseases 4Immunoblastic Lymphadenopathy 4

Interventions

venetoclax 6ibrutinib 3fludarabine phosphate 3Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2pirtobrutinib 1pembrolizumab 1obinutuzumab 1fludarabine 1carmustine, poliferprosan 20 drug combination 1acalabrutinib 1Tacrolimus 1Nivolumab 1Melphalan 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 1Bendamustine Hydrochloride 1Atorvastatin 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chromosome 17 deletion × Bendamustine Hydrochloride × Lymphoid × Clear all
NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie

Phase 3 Completed
120 enrolled 14 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡